A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.

2.50
Hdl Handle:
http://hdl.handle.net/10541/621265
Title:
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.
Authors:
Gollins, S; West, N; Sebag-Montefiore, D; Susnerwala, S; Falk, S; Brown, N; Saunders, Mark P; Quirke, P; Ray, R; Parsons, P; Griffiths, G; Maughan, T; Adams, R; Hurt, C
Abstract:
Neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC.
Affiliation:
North Wales Cancer Treatment Centre, Bodelwyddan, Denbighshire, LL18 5UJ, UK
Citation:
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. 2018, Br J Cancer
Journal:
British Journal of Cancer
Issue Date:
15-Aug-2018
URI:
http://hdl.handle.net/10541/621265
DOI:
10.1038/s41416-018-0209-4
PubMed ID:
30116024
Type:
Article
Language:
en
ISSN:
1532-1827
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGollins, Sen
dc.contributor.authorWest, Nen
dc.contributor.authorSebag-Montefiore, Den
dc.contributor.authorSusnerwala, Sen
dc.contributor.authorFalk, Sen
dc.contributor.authorBrown, Nen
dc.contributor.authorSaunders, Mark Pen
dc.contributor.authorQuirke, Pen
dc.contributor.authorRay, Ren
dc.contributor.authorParsons, Pen
dc.contributor.authorGriffiths, Gen
dc.contributor.authorMaughan, Ten
dc.contributor.authorAdams, Ren
dc.contributor.authorHurt, Cen
dc.date.accessioned2018-09-30T15:38:11Z-
dc.date.available2018-09-30T15:38:11Z-
dc.date.issued2018-08-15-
dc.identifier.citationA prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. 2018, Br J Canceren
dc.identifier.issn1532-1827-
dc.identifier.pmid30116024-
dc.identifier.doi10.1038/s41416-018-0209-4-
dc.identifier.urihttp://hdl.handle.net/10541/621265-
dc.description.abstractNeoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC.en
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleA prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.en
dc.typeArticleen
dc.contributor.departmentNorth Wales Cancer Treatment Centre, Bodelwyddan, Denbighshire, LL18 5UJ, UKen
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.